Sanaria Inc.

Name

Sanaria Inc.

Legal name

Sanaria Inc.

Website

https://sanaria.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Malaria Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Travel & Tropical Disease Vaccines (HLAIAEAE)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ)

Keywords

• Malaria vaccine development
• Whole-parasite vaccines
• Plasmodium research reagents
• Controlled human infection
• Biotechnology manufacturing

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure

Revenue model

1. Research Reagents and Products: Sale of aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites, Plasmodium reagents, Anopheles mosquitoes, assay services, and custom manufacturing to research institutions
2. Vaccine Development: Development of malaria vaccines for prevention in individuals and in combination with other malaria control measures to halt transmission and eliminate malaria from communities

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Sanaria develops whole-parasite malaria vaccines based on its proprietary Plasmodium falciparum sporozoite (PfSPZ) platform, including radiation-attenuated (PfSPZ Vaccine), chemo-attenuated (PfSPZ-CVac), and genetically engineered late-arresting (PfSPZ-LARC2) candidates. The company also manufactures and sells a family of aseptic, purified, cryopreserved malaria research reagents, assay services (aIFA, aISI, ELISA), PfSPZ Challenge mosquitoes, antibodies, and custom manufacturing services to research institutions worldwide.

Product overview

Sanaria Inc. is a biotechnology company developing whole-parasite malaria vaccines and providing related research products and services. The core product portfolio includes three vaccine candidates in various clinical stages: Sanaria® PfSPZ Vaccine (radiation-attenuated, Phase 2), Sanaria® PfSPZ-LARC2 Vaccine (genetically engineered, single-dose, Phase 1), and Sanaria® PfSPZ-CVac (chemo-attenuated with antimalarial drugs, Phase 2). Supporting the vaccine development pipeline, Sanaria offers a comprehensive family of research reagents and services including PfSPZ Reagents, Plasmodium Reagent Slides, PfSPZ Challenge Mosquitoes, Anopheles Reagents, Antibodies (MAbPfEXP-1, MAbPfCelTOS), and assay services (aIFA, aISI, ELISA). All products are manufactured in a cGMP-compliant industrial setting.

Differentiator

Problem solved

Functional benefit

Brands

• Sanaria Family of Products and Services: A catalog of reagents and services including PfSPZ Reagents, Plasmodium Reagent Slides, Assay Services (aIFA, aISI, ELISA), PfSPZ Challenge Mosquitoes, Anopheles Reagents, Antibodies, and Custom Services for malaria research.

Products and services

• Sanaria PfSPZ Vaccine Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoite vaccine designed to prevent malaria infection; currently in Phase 2 clinical studies.
• Sanaria PfSPZ-LARC2 Vaccine Late arresting replication competent whole-parasite malaria vaccine designed to provide high-level protection against Plasmodium falciparum with a single dose. Developed in collaboration with Seattle Children's Research Institute.
• Sanaria PfSPZ-CVac Infectious PfSPZ vaccine administered with malaria chemoprophylaxis (chloroquine or pyrimethamine); currently in Phase 2 clinical studies and demonstrated 100% protective efficacy against heterologous controlled human malaria infection 12 weeks after vaccination.
• Sanaria PfSPZ Reagents Aseptic, purified, vialed, cryopreserved, attenuated and non-attenuated Plasmodium falciparum sporozoites for laboratory-based research studies. Sold to research institutions worldwide.
• Sanaria Plasmodium Reagent Slides

Quantifiable outcome

• 77% protection rate against heterologous controlled human malaria infection 12 weeks after vaccination with PfSPZ-CVac
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• PATH Malaria Vaccine Initiative (MVI)coreStrategic or Co-development PartnerPartnership established in 2006 to accelerate development of Sanaria's unique malaria vaccine candidate. MVI and Sanaria conducted initial safety and test-of-concept trials. Partnership included opening of clinical manufacturing facility in 2007.
• Seattle Children's Research InstitutecoreStrategic or Co-development PartnerCo-development of PfSPZ-LARC2 Vaccine - a whole malaria parasite vaccine strain that infects the liver and gets completely stuck, unable to cause blood infection. Joint publication in EMBO Molecular Medicine March 2024. Co-host i-PfSPZ-C meetings.
• Government of Equatorial GuineacoreStrategic or Co-development PartnerLong-term partnership since 2004 for the Bioko Island Malaria Elimination Project (BIMEP). Partnership includes Marathon Oil, Noble Energy, AMPCO, and Equatorial Guinea LNG. Dedicated to elimination of malaria from Bioko Island where it was a leading cause of morbidity and mortality.
• University of Tübingen / German Center for Infection Research (DZIF)coreStrategic or Co-development PartnerKey collaborator on PfSPZ-CVac vaccine development and clinical trials. Professor Peter Kremsner leads studies demonstrating 77-100% protective efficacy. DZIF workshop on malaria vaccine development focuses on PfSPZ-LARC2 Vaccine at Paul-Ehrlich-Institut.
• International PfSPZ Consortium (i-PfSPZ-C)coreStrategic or Co-development PartnerGlobal collaboration network with semi-annual meetings. 2025 meeting in Toronto brought together 48 scientists from 11 countries. Consortium includes researchers from US, Europe, and Africa coordinating vaccine and clinical development strategies.
• Malaria No MoreminorGTM or Marketing PartnerAdvocacy organization dedicated to ending malaria. Organized World Malaria Day Exhibition at Rayburn House Office Building in Washington DC. CEO Bill Steiger visited Sanaria facilities in May 2026.
• Protein Potential, LLCcoreStrategic or Co-development PartnerCo-located in Rockville, Maryland with Sanaria. Collaboration on COVID-19 vaccine development (OraCOV vaccine). Dr. Kim Lee Sim serves as President/CSO at Protein Potential and Executive VP of Process Development and Manufacturing at Sanaria.
• Malaria Research and Training Center (MRTC), MalicoreStrategic or Co-development PartnerCollaborator on NIH-funded PfSPZ-CVac malaria vaccine development. Clinical trials in Mali including studies in adults and women of childbearing potential.
• Groupe de Recherche Action en Santé (GRAS), Burkina FasominorStrategic or Co-development PartnerPhysician-scientists at GRAS in Burkina Faso conducting initial safety evaluations of PfSPZ-LARC2 Vaccine in 30 adult Burkinabé participants.
• U.S. Naval Medical Research CentercoreStrategic or Co-development PartnerClinical trial site partner. Phase 1 trial conducted at US Naval Medical Research Center Clinical Trials Center in Bethesda.
• University of Maryland School of MedicinecoreStrategic or Co-development PartnerCollaborator on clinical trials and NIH-funded research. Phase 1 trial site at Center for Vaccine Development in Baltimore.

Scale indicators11 records

Recent moves3 records

Expansion highlights5 records

Direct peers

• GSK: GSK developed RTS,S/AS01 (Mosquirix), the first WHO-recommended malaria vaccine targeting P. falciparum in children. It is the most directly comparable competitor to Sanaria's PfSPZ platform in the same indication and end market.
• Serum Institute of India: Co-developer and manufacturer of the R21/Matrix-M malaria vaccine with Oxford's Jenner Institute, approved in multiple African countries at sub-$5 per dose. Directly competes with Sanaria in the same P. falciparum pediatric market with a scaled, low-cost alternative.
• University of Oxford (Jenner Institute): Originator of the R21/Matrix-M malaria vaccine, which has achieved WHO prequalification and is being deployed across endemic regions. Direct peer given overlapping P. falciparum vaccine target and global-health funding ecosystem.

Emerging players

• BioNTech: Developing mRNA-based malaria vaccine candidates (BNT165) toward clinical evaluation. Comparable as a next-generation platform challenger in the malaria vaccine race, though with a different technology architecture than Sanaria's whole-parasite approach.
• Moderna: Advancing mRNA-1640 and related malaria mRNA vaccine candidates. Operates in the same global-health infectious-disease space with a different technology platform, pursuing the same P. falciparum indication.

Broad incumbents

• Novavax: Vaccine platform company with Matrix-M adjuvant technology underpinning R21/Matrix-M and broader infectious-disease pipeline. Comparable as an established vaccine platform player in global health, though more diversified across indications than Sanaria.

Regional players

• Bharat Biotech: Indian vaccine manufacturer with a malaria vaccine candidate (BBV87) and a broad global-health portfolio. Comparable as a manufacturer of cost-effective vaccines for endemic-region markets, with regional strengths overlapping Sanaria's Africa/Asia clinical footprint.

Others

• PATH Malaria Vaccine Initiative: Global-health non-profit product development partner and long-standing Sanaria collaborator (PATH MVI partnership since 2006). Comparable as an influential funder/partner shaping malaria vaccine development strategy and donor priorities.
• Leidos Holdings (via contracted NIAID work): Operates vaccine biodefense and infectious-disease R&D programs including malaria-related work for U.S. government clients. Comparable as a contractor/ecosystem participant in malaria and emerging infectious disease research adjacent to Sanaria's NIAID-funded pipeline.
• Protein Potential, LLC: Co-located Rockville biotech and Sanaria co-developer of the OraCOV oral COVID-19 vaccine, with shared executive leadership (Dr. B. Kim Lee Sim). Comparable as a closely adjacent vaccine development partner using similar platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/sanaria_inc
• Facebookfacebook.com/sanaria-inc-82950019452

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanaria Inc.